User:Lan.wang17/Enter your new article name here

{{Userspace draft|source=ArticleWizard|date=December 2010}}

Matthew Chervenak is the founder, President and CEO of [http://www.gbipharma.com General Biologic] (GBI), a China-focused healthcare consulting and data intelligence company.http://www.businessweek.com/globalbiz/content/sep2007/gb20070912_513202.htm He also serves as the Chairman of the Shanghai American Chamber of Commerce- Healthcare Committee.http://www.amcham-shanghai.org/amchamportal/committees/Committeeabout.aspx?CommitteeID=26 Prior to establishing General Biologic, Chervenak was a strategist at Sapient Corporation in New York City and researcher at New York University Medical Center and the National Institutes of Health.http://www.terrapinn.com/2009/bma/SPK-mr-matthew-CHERVENAK.stm Chervenak graduated with a B.S. in Biology from Pennsylvania State University. http://www.techvision.com/bpc/program/index.php?pageid=306

Chervenak regularly contributes to international publications and speaks at industry conferences about China's pharmaceutical and biotechnology sectors. Chervenak believes that China is an ideal base for global biogenerics.http://journals2005.pasteur.ac.ir/DDT/10(17).pdf In his China Business Review editorial, Chervenak said that China's low-cost, highly skilled technologists and scientists, a strong track record in life-science research, a high-quality returnee pool, advantageous policies and tax treatment, and China's entrepreneurial culture makes it a bright future for China's life sciences industry.http://www.chinabusinessreview.com/public/0505/chervenak.html Even in the controversial topic of IP in the life sciences field in China, according to Chervenak, as long as a foreign biotech firm protects its IP for the most lucrative markets, it is usually not worth being overly concerned about a Chinese company violating IP use in China, where the market is still small.http://www.nature.com/nbt/journal/v22/n7/box/nbt0704-789_BX1.html